How long does dry eyes last during perimenopause?

Dry eye symptoms during perimenopause can develop gradually over months to years and, unlike some acute perimenopausal symptoms, tend to persist and sometimes worsen through the transition and into postmenopause without treatment. This is because the underlying mechanisms reflect structural and functional changes in the tear-producing glands and ocular surface that do not simply reverse when hormonal volatility ends. For many women, dry eyes are a long-term feature of hormonal change rather than a temporary symptom of the perimenopausal transition.

Estrogen, androgen, and progesterone receptors are all expressed in the ocular structures responsible for tear production and tear film stability. The lacrimal glands, which produce the aqueous component of tears, respond to hormonal signals, as do the meibomian glands, specialized sebaceous glands in the eyelids that produce the lipid layer of the tear film. This lipid layer is critical because it sits on top of the aqueous layer and prevents rapid evaporation. The conjunctival goblet cells, which produce mucin, the component that allows tears to spread evenly across the corneal surface, are also hormonally responsive. All three layers of the tear film can be compromised by the hormonal changes of perimenopause.

Meibomian gland dysfunction is a particularly important component. These glands require adequate androgen stimulation to produce the lipid secretions that form the outer tear film layer. As the hormonal environment shifts during perimenopause and postmenopause, meibomian gland function can become impaired, producing a tear film with inadequate lipid protection. The result is that even when aqueous tear production is adequate, tears evaporate too quickly, producing evaporative dry eye: gritty, stinging, tired-feeling eyes despite a moist surface.

The relationship between estrogen therapy and dry eye is nuanced and somewhat counterintuitive. Some research, including data from the Women's Health Study, found that postmenopausal women using estrogen-only therapy had higher rates of dry eye diagnosis than those not using hormone therapy. The proposed explanation is that exogenous estrogen without androgen supplementation may further suppress the androgen-dependent meibomian gland function that is critical for the lipid layer. Women using combined estrogen-progestogen therapy showed lower rates than estrogen-only users. This finding does not mean hormone therapy causes dry eye for everyone, but it highlights that the relationship is complex and worth discussing with providers.

Symptoms include eyes that feel gritty, scratchy, burning, or fatigued. Paradoxically, reflex tearing can occur, producing watery eyes as the cornea signals distress, though the underlying dryness remains. Light sensitivity, blurred vision that temporarily clears with blinking, difficulty with extended screen time, and discomfort or intolerance with contact lenses are common features. Dry eye often worsens in low-humidity environments such as air-conditioned offices or pressurized airplane cabins, and with extended screen use, which reduces blink rate.

For most women, dry eye symptoms do not spontaneously resolve after menopause. In the absence of treatment, symptoms often gradually worsen as the ocular surface continues to lose the hormonal support it relied on for decades. The good news is that effective treatments exist at multiple levels. Preservative-free artificial tears are the first-line approach and should be applied proactively rather than only when symptoms are severe, typically four or more times daily in the early management phase. Warm compresses applied to closed eyelids for 10 minutes, followed by gentle eyelid massage, unclog meibomian glands and improve the quality of lipid secretion. Omega-3 fatty acid supplementation (with combined EPA and DHA at around 3 grams daily from fish oil) has demonstrated benefit for meibomian gland dysfunction and tear film stability in randomized trials. For moderate to severe cases, prescription cyclosporine eye drops (Restasis, Cequa) or lifitegrast drops (Xiidra) reduce ocular surface inflammation that perpetuates dry eye. Punctal plugs that partially block the tear drainage channels preserve natural tears and significantly improve comfort in women who have not responded adequately to drops alone.

Tracking your symptoms over time, using a tool like PeriPlan, can help you monitor changes in eye comfort alongside other perimenopausal symptoms and identify whether specific triggers such as screen time, indoor environments, or new medications are worsening your eyes, providing useful information for your provider.

When to talk to your doctor: Speak with an eye care provider if dry eye symptoms are significantly affecting your vision, daily comfort, or contact lens tolerance, or if over-the-counter drops are not providing adequate relief. Also seek evaluation for any sudden change in vision quality, persistent eye redness with pain, or symptoms that do not fit the gradual pattern of evaporative dry eye. Formal evaluation including tear film testing, meibomian gland assessment, and slit-lamp examination can identify the specific type of dry eye and guide targeted treatment.

This content is for informational purposes only and does not replace medical advice. Always consult your healthcare provider about your specific situation.